Activity of InvivoGen's Anti-CoV2RBD Monoclonal Antibodies
InvivoGen's anti-CoV2RBD monoclonal antibodies (mAbs) have been tested in house to compare their activity. The tests consist of Lucia luciferase-based ELISA and FACS screening assays that have been performed using:
- RBD-Lucia proteins, a collection of Lucia luciferase-tagged Spike RBD proteins from SARS-CoV-2 variants (including the variants of concern), or
- 293-SARS2-S-dfur cells, a series of HEK293-derived cells expressing at the surface the Spike protein of the variants of concern.
Below are the data obtained with the following anti-SARS-CoV2 Spike antibodies featuring a mouse IgG2a constant region:
Figure 1: Lucia Luciferase-based ELISA
The binding capacity of InvivoGen's anti-SARS-CoV2RBD mAbs to a set of Spike variants has been validated using a Lucia luciferase-based ELISA.
Anti-murine IgG F(ab’)2 fragment (2 µg/ml) was coated on an ELISA plate overnight. Anti-CoV2RBD-cas-mIgG2a, Anti-CoV2RBD-imd-mIgG2a, Anti-CoV2RBD-bam-mIgG2a, Anti-CoV2RBD-ete-mIgG2a along with RBD-Lucia proteins (original and V2 to V8; 1 µg/ml) were added and incubated for 2 hours at room temperature. After washing (3x times), binding affinity was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI-Luc™. Data are shown as a fold change over no antibody.
Figure 2: FACS screening assays
InvivoGen's anti-SARS-CoV2RBD mAbs allow the detection of Spike surface expression by mammalian cells for a set of SARS-CoV-2 variants of concern.
Human embryonic kidney (HEK)-293 cells featuring stable cell surface expression of Spike variants were incubated with either Anti-CoV2RBD-cas-mIgG2a, Anti-CoV2RBD-imd-mIgG2a, Anti-CoV2RBD-bam-mIgG2a, or Anti-CoV2RBD-ete-mIgG2a mAbs for 1 hour at 4°C. Cells were then washed and incubated with a PE-conjugated goat anti-murine IgG for 1 hour at 4°C, and surface staining was analyzed by FACS. The grey line indicates the maximal fluorescence intensity for unstained cells.